DE69529958D1 - Aminoalkyloxime, Verfahren zur dessen Herstellung, ihre Verwendung als Medikamente und Zwischenprodukte - Google Patents

Aminoalkyloxime, Verfahren zur dessen Herstellung, ihre Verwendung als Medikamente und Zwischenprodukte

Info

Publication number
DE69529958D1
DE69529958D1 DE69529958T DE69529958T DE69529958D1 DE 69529958 D1 DE69529958 D1 DE 69529958D1 DE 69529958 T DE69529958 T DE 69529958T DE 69529958 T DE69529958 T DE 69529958T DE 69529958 D1 DE69529958 D1 DE 69529958D1
Authority
DE
Germany
Prior art keywords
preparation
oximes
aminoalkyl
medicines
intermediates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69529958T
Other languages
English (en)
Other versions
DE69529958T2 (de
Inventor
Gregory Shutske
Brian S Freed
John Dick Tomer
R Richard L Hamer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Publication of DE69529958D1 publication Critical patent/DE69529958D1/de
Application granted granted Critical
Publication of DE69529958T2 publication Critical patent/DE69529958T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
DE69529958T 1994-08-03 1995-07-28 Aminoalkyloxime, Verfahren zur dessen Herstellung, ihre Verwendung als Medikamente und Zwischenprodukte Expired - Fee Related DE69529958T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/285,668 US5665756A (en) 1994-08-03 1994-08-03 Aminoalkyloximes useful in the treatment of depression and obsessive compulsive disorders
US285668 1994-08-03

Publications (2)

Publication Number Publication Date
DE69529958D1 true DE69529958D1 (de) 2003-04-24
DE69529958T2 DE69529958T2 (de) 2004-01-08

Family

ID=23095223

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69529958T Expired - Fee Related DE69529958T2 (de) 1994-08-03 1995-07-28 Aminoalkyloxime, Verfahren zur dessen Herstellung, ihre Verwendung als Medikamente und Zwischenprodukte

Country Status (9)

Country Link
US (8) US5665756A (de)
EP (1) EP0709378B1 (de)
JP (1) JP3947238B2 (de)
AT (1) ATE234820T1 (de)
CA (1) CA2155275C (de)
DE (1) DE69529958T2 (de)
DK (1) DK0709378T3 (de)
ES (1) ES2194033T3 (de)
PT (1) PT709378E (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2670236C (en) * 1999-09-30 2012-06-05 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
DE19952146A1 (de) * 1999-10-29 2001-06-07 Boehringer Ingelheim Pharma Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US7256191B2 (en) * 2000-04-24 2007-08-14 Aryx Therapeutics Materials and methods for the treatment of depression
JP2003531169A (ja) 2000-04-24 2003-10-21 アリックス セラピューティクス うつ病治療のための材料と方法
US8193768B2 (en) * 2008-02-28 2012-06-05 Jason S. Hallett Contactless charging system for musical instruments
US11498903B2 (en) 2017-08-17 2022-11-15 Bristol-Myers Squibb Company 2-(1,1′-biphenyl)-1H-benzodimidazole derivatives and related compounds as apelin and APJ agonists for treating cardiovascular diseases

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3692835A (en) * 1967-04-05 1972-09-19 Jan Van Dijk Pharmacologically active amino-ethyl oximes
BE759128R (fr) * 1969-11-18 1971-05-18 Usv Pharma Corp Carbamoyl oximes et leur methode de
FR2162312B1 (de) * 1971-12-10 1975-02-07 Buzas Andre
FR2215953B2 (de) * 1973-02-05 1976-05-14 Buzas Andre
US4192893A (en) * 1975-03-20 1980-03-11 U.S. Philips Corporation Anti-depressive compounds
NL7503313A (en) * 1975-03-20 1976-09-22 Philips Nv Antiaggressive oxime ethers - viz 4-nitro-2-butyl(oxy)-acetophenone O-aminoalkyl-oximes
NL7503310A (nl) * 1975-03-20 1976-09-22 Philips Nv Verbindingen met antidepressieve werking.
NL7610399A (en) * 1976-09-20 1978-03-22 Philips Nv O-Aminoethyl oxime derivs. of halophenyl ketone cpds. - are selective nor-adrenalin potentiators useful as antidepressants
GR61620B (en) * 1976-10-14 1978-12-04 Byk Gulden Lomberg Chem Fab Preparation process of pyrazol-1-yl-phenyloxic acids
DE2658762A1 (de) * 1976-12-24 1978-06-29 Hoechst Ag Neue o-alkylierte oxime, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE2658938A1 (de) * 1976-12-24 1978-07-06 Hoechst Ag Neue basisch substituierte 0-propyloxime, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4297359A (en) * 1978-07-25 1981-10-27 Acf Chemiefarma Nv Anti-ulcer compositions containing certain pyridyl oxime ethers
US4352804A (en) * 1978-07-25 1982-10-05 Acf Chemiefarma Nv Oxime ethers, their preparation and pharmaceutical compositions containing them
AU532700B2 (en) * 1979-04-02 1983-10-13 Sumitomo Chemical Company, Limited Diphenylalkanoether
DE3019497A1 (de) * 1980-05-22 1981-11-26 Bayer Ag, 5090 Leverkusen Aminopropiophenon-derivate, verfahren zu ihrer herstellung und ihre verwendung als fungizide
WO1981003579A1 (en) * 1980-06-07 1981-12-10 Hell R Gmbh High stability electron gun for the shaping of materials
EP0053017B1 (de) * 1980-11-24 1985-02-20 Imperial Chemical Industries Plc Amid-Derivate
US4851423A (en) * 1986-12-10 1989-07-25 Schering Corporation Pharmaceutically active compounds
JPS6463574A (en) * 1987-09-03 1989-03-09 Mitsubishi Chem Ind Ethanone oximes
GB8811056D0 (en) * 1988-05-10 1988-06-15 Ici Plc Antibiotic compounds
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
DE3927483A1 (de) * 1989-08-19 1991-02-21 Boehringer Ingelheim Kg Neue substituierte heterocyclische fuenfringe, ihre herstellung und verwendung
IL97144A (en) * 1990-02-27 1994-11-28 Erba Carlo Spa History of 1-) Alkoxy-Iminoalkyl (Imidazole Transformed Preparation and Pharmaceutical Preparations Containing Them

Also Published As

Publication number Publication date
US5648367A (en) 1997-07-15
US5696142A (en) 1997-12-09
PT709378E (pt) 2003-06-30
JPH0859617A (ja) 1996-03-05
US5665756A (en) 1997-09-09
ES2194033T3 (es) 2003-11-16
US5686483A (en) 1997-11-11
US5686447A (en) 1997-11-11
EP0709378A2 (de) 1996-05-01
ATE234820T1 (de) 2003-04-15
EP0709378A3 (de) 1996-10-02
CA2155275A1 (en) 1996-02-04
US5686446A (en) 1997-11-11
JP3947238B2 (ja) 2007-07-18
US5684021A (en) 1997-11-04
US5770740A (en) 1998-06-23
EP0709378B1 (de) 2003-03-19
CA2155275C (en) 2007-05-15
DK0709378T3 (da) 2003-07-14
DE69529958T2 (de) 2004-01-08

Similar Documents

Publication Publication Date Title
NO932870L (no) Ny fremgangsmaate for fremstilling av 9-amino-6-demetyl-6-deoksyetracykliner
ATE218576T1 (de) Phosphohalohydrine, verfahren zu deren herstellung und verwendungen
DE69311260T2 (de) Verfahren zur Herstellung von (E)-Alkoximino- oder Hydroxyiminoacetamidverbindungen und Zwischenprodukte
DE69231815T2 (de) Verfahren zur Herstellung von Cephalosporinen und Zwischenprodukte in diesem Verfahren
ATE166355T1 (de) Substituierte aminothienopyridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE206926T1 (de) Verwendung eines phosphorsäurediesters zur herstellung eines arzneimittels zur behandlung von akne
DE69529958D1 (de) Aminoalkyloxime, Verfahren zur dessen Herstellung, ihre Verwendung als Medikamente und Zwischenprodukte
DE59509910D1 (de) Verfahren zur Herstellung von Alkylhydrogenchlorsilanen
DE60235365D1 (de) Verfahren zur herstellung von 7-amino-syn-3,5-dihydroxyheptansäurederivaten und zwischenverbindungen diesesverfahrens und deren herestellung
ATE407127T1 (de) Verfahren zur herstellung von beraprost und dessen salzen
ATE193281T1 (de) Verfahren zur herstellung von 2-(2- hydroxymethylphenyl)acetamid-derivaten und zwischenprodukte zur herstellung
DE60224884D1 (de) Verfahren zur herstellung von 3, 3', 6, 6'-tetraalkylen-2, 2'-biphenolen und 3, 3', 6, 6'-tetraalkylen-5, 5'-dihalo-2, 2' biphenolen
ATE270287T1 (de) 2,3-dihydro-1h-isoindolderivate, verfahren zu ihrer herstellung und ihre verwendung als hemmer der serotoninwiederaufnahme
ATE267832T1 (de) Substanz gm-95, verfahren zu ihrer herstellung und ihre verwendung
ATE211136T1 (de) Coumarin-derivate, verfahren zu deren herstellung und deren verwendung
ATE234288T1 (de) Verfahren zur herstellung eines buthylthuio- isochinolinderivates und zwischenprodukte dafür
ATE265421T1 (de) Verfahren zur herstellung von midodrin
DE60144570D1 (de) Verfahren zur herstellung von optisch aktiven sulfonamiden und zwischenprodukte zur deren synthese
ATE179417T1 (de) Glyceraldehyd-3-pentanid und verfahren zu ihrer herstellung
ATE200290T1 (de) Verfahren zur herstellung von indolocarbazol- derivaten
ES2085540T3 (es) 2-(3-fenilpropil)hidrazinas, productos intermedios en y un procedimiento para la preparacion de las mismas, y su uso como medicamentos.
DE50007412D1 (de) Verfahren zur herstellung von n-substituierten 2,4-diamino-5-fluor-benzonitrilen und neue zwischenprodukte
DE69910626D1 (de) Verfahren zur herstellung von 1,4-diaryl-2-fluor-1,3-butadien- und 1,4-diaryl-2-fluor-2-butenverbindungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: AVENTIS HOLDINGS INC., GREENVILLE, DEL., US

8339 Ceased/non-payment of the annual fee